1 is an Ets family transcription factor and involved in lymphoid and myeloid cell development and specific gene regulation. PU.1 is expressed in lymphoid cells, macrophages, dendritic cells (DC), 3 neutrophils, and mast cells in a cell type-specific manner (1) . The necessity of PU.1 for generation of these lineages was shown by PU.1 knockout mouse that abolishes macrophage and B cell production and delays neutrophil and T cell production (2) (3) (4) . The requirement of PU.1 for the development of DC and mast cells was also recently revealed by the analyses using PU.1 knockout mouse (5-7). It was also reported that expression level of PU.1 determines cell fate between B cells/macrophages (8) and neutrophils/macrophages (9) . In addition, recent analyses demonstrated that overexpression of PU.1 in CD34 ϩ human myeloid progenitors triggers development of Langerhans cells (LC) (10, 11) .
Recently, we found that overproduction of PU.1 in mouse bone marrow-derived hemopoietic progenitor cells developing toward mast cells induced the expression of several monocyte-specific genes and caused morphological change (12) . In this study, we conducted overexpression of PU.1 by retrovirus transfection system in differentiated mast cells, mouse bone marrow-derived mast cells (BMMC), and peritoneal mast cells (PMC), and examined its effect on the expression of monocyte-and mast cell-specific markers and the cell morphology. BMMC and PMC showed several monocytic characteristics by overproduction of PU.1, suggesting that PU.1 functions to promote monocyte-specific gene expression even in developed mast cells, and that developed mast cells still possess the potential capacity to exhibit several monocytic features.
Materials and Methods

Cells
A retrovirus packaging cell, Plat-E (13), was maintained in DMEM (Sigma-Aldrich) supplemented with 10% heat-inactivated FBS (SigmaAldrich), 100 U/ml penicillin, 100 g/ml streptomycin, 1 g/ml puromycin (Sigma-Aldrich), and 10 g/ml blasticidin (Funakoshi). To generate BMMC, bone marrow cells prepared from BALB/c (Japan SLC, Hamamatsu, Japan) were grown in RPMI 1640 (Sigma-Aldrich) supplemented with 10% heatinactivated FBS, 100 M 2-ME, 10 M MEM nonessential amino acids solution (Sigma-Aldrich), 100 U/ml penicillin, 100 g/ml streptomycin, and 10% pokeweed mitogen-stimulated spleen-condition medium (14) . After 4-wk culture, Ͼ95% of cells were identifiable as mast cells by toluidine blue staining and as c-kit ϩ /Fc⑀RI ϩ by flow cytometric analysis. Mouse PMC was prepared from whole peritoneal cells by density-gradient centrifugation techniques using metrizamide (Sigma-Aldrich) with Ͼ98% purity (15) , and was maintained in RPMI 1640 supplemented with 10% FBS, 10% pokeweed mitogen-stimulated spleen-condition medium, 20 ng/ml mouse recombinant stem cell factor (PeproTech), and antibiotics (penicillin and streptomycin). Bone marrow-derived DC (BMDC) was prepared according to previously reported method (16, 17) , with some modifications. In brief, bone marrow cells prepared from BALB/c were grown in RPMI 1640 supplemented with 10% FBS, 100 M 2-ME, 10 M MEM nonessential amino acids solution, antibiotics, 10 ng/ml mouse rGM-CSF (PeproTech), and 10 ng/ml mouse rIL-4 (PeproTech). Peritoneal macrophages were obtained from BALB/c, as described previously (18) . Briefly, peritoneal exudate cells were harvested from mice, which received i.p. 2 ml of 4% thioglycolate (SigmaAldrich) 4 days before, by peritoneal lavage with ice-cold PBS. After 1-h culture on a plastic dish, nonadherent cells were collected and used as peritoneal macrophages. pMX-IG (22) using restriction endonucleases and a DNA ligation kit, version 1 (Takara BIO), to generate pMX-IG-PU.1.
Transfection
Infection of BMMC and PMC was performed, according to a previously reported method (12, 20) . In brief, pMX-puro (mock vector) and pMXpuro-PU.1 (for the expression of wild-type PU.1) were transiently introduced into Plat-E with Fugene6 (Roche Diagnostics). BMMC after 4-wk culture and freshly prepared PMC were incubated with harvested culture medium of transfected Plat-E containing infectious viruses for 2 days in the presence of 10 g/ml polybrene (Sigma-Aldrich). Infected cells were selected by culture in the presence of 1.2 g/ml puromycin for 10 -20 days. When pMX-IG and pMX-IG-PU.1 were used for transfection, transfectants that were obtained by the same method as that of pMX-puro-series described above were selected as GFP-positive cells.
Western blotting analysis
To detect endogenous PU.1, BMMC was stimulated by 1 g/ml LPS or 100 mg/ml PMA (Sigma-Aldrich) for 0 -48 h. Whole cells were subjected to Western blotting analysis. Rabbit polyclonal Ab against PU.1 (Santa Cruz Biotechnology) or mouse mAb against Flag-tag (Sigma-Aldrich) was used as the primary Ab. Alexa Fluor 680 goat anti-rabbit IgG or Alexa Fluor 680 goat anti-mouse IgG (Molecular Probes) was used as the secondary Ab. Infrared fluorescence on membranes was detected by Odyssey infrared imaging system (model ODY-9201-SC; LI-COR).
Flow cytometric analysis
The FITC-or PE-conjugated anti-mouse Abs against I-A d , CD11b, CD11c, F4/80, and c-kit, all of which were purchased from BD Pharmingen, were used to stain each cell surface molecule after blocking Fc receptors with 2.4G2 (BD Pharmingen). Mouse IgE Ab (BD Pharmingen) conjugated with FITC was used to stain mouse Fc⑀RI. To stain TLR2 and 4, antimouse TLR2 and 4 rat IgG mAbs purchased from HyCult Biotechnology were used as the first Ab, respectively, and FITC-conjugated rabbit F(abЈ) 2 anti-rat IgG Ab (Valeant Pharmaceuticals) was used as the second Ab. In the case of pMX-IG-series transfectants expressing GFP, cells were stained with PE-conjugated anti-mouse c-kit and allophycocyanin-conjugated antimouse CD11b, CD11c, or combination of biotin-labeled anti-mouse I-A d and streptavidin-allophycocyanin (BD Pharmingen). For sorting of c-kitpositive or c-kit/Fc⑀RI-double-positive cells, BD FACSAria Cell Sorter (BD Biosciences, San Jose, CA) was used. Cells stained with each Ab, as described previously (23, 24) , were analyzed by FACSCalibur flow cytometer (BD Biosciences).
Morphological analysis
Electron microscopy and May-Grünwald-Giemsa's staining were performed, as described previously (12) .
LPS, peptidoglycan (PGN), and Ag/IgE stimulation
Culture medium of cells stimulated with LPS (from Escherichia coli; Sigma-Aldrich), PGN (from Staphylococcus aureus; Sigma-Aldrich), or Ag/ IgE was harvested after 6-h incubation. Stimulation with Ag/IgE was performed according to a previously published method (25) . Concentrations of IL-6 in the culture supernatant were determined by an ELISA kit, according to the manufacturer's instruction (Genzyme Techne, Minneapolis, MN). ␤-Hexosaminidase-releasing assay was performed with previously reported method (25) to investigate degranulation activity.
Ag presentation assay
Cells irradiated at a dose of 30 Gy were plated into 96-well round-bottom plates at 5-fold serial dilutions, each well of which contained splenic CD4 ϩ T cells from C57BL/6 mice at 3 ϫ 10 5 , and incubated for 2 days. [ 3 H]Thymidine was then added (0.37 Mbq/well), and incubation was continued for an additional 15 h.
Results
Overproduction of PU.1 in BMMC induced the expression of MHC class II, CD11b, CD11c, and F4/80, and suppressed the expression of c-kit
To examine the effect of overproduced PU.1 in mast cells, BMMC were transfected with retrovirus vector that directed the production of wild-type PU.1 or empty vector (Fig. 1A) . In Western blotting analysis using anti-PU.1 Ab (Fig. 1B) , apparent production of wild-type PU.1 was observed, while endogenous PU.1 was not detected under the conditions used (see 
Morphology of transfectants
To investigate the effect of PU.1 overproduction on the morphology of the cells, May-Grünwald-Giemsa staining of cytospun ( Fig. 2A ) and electron microscopy ( Fig. 2B) were performed. The mock transfectants contained a large amount of granules as well as control BMMC. In contrast, PU.1-overproducing cells contained lesser amount of granules, but showed macrophage-and DC-like morphology characterized by vacuoles in the cytoplasm, larger veils, and lamellipodia extending from cell bodies. These observations showed that overproduction of PU.1 caused monocyte-like morphological change on BMMC.
Response to LPS and PGN stimulation
TLR4 signaling activated by LPS induces DC and macrophages to produce proinflammatory cytokines, including IL-6 (26) . Although mast cells also produce IL-6 in response to LPS, the production level is quite lower than that of monocytes (27) . We therefore analyzed the IL-6 production level of PU.1-overproducing cells by LPS stimulation (Fig. 3A) . The amount of IL-6 produced by LPS stimulation was markedly increased in cells overproducing wildtype PU.1 as well as BMDC. In contrast, mock transfectants produced IL-6 at the level similar to that of BMMC.
To confirm the specificity of TLR signaling, we next analyzed the response to PGN, which activates cells via TLR2, by measuring IL-6 released from each transfectant (Fig. 3B) . Overproduction of PU.1 resulted in markedly increased production of IL-6 in response to PGN stimulation.
Recently, it has been reported that the essential elements in the promoters of TLR2 and 4 genes were recognized by PU.1 (28, 29) , suggesting the possibility that overproduction of PU.1 might enhance IL-6 production through increased expression of TLR2 and 4. We therefore analyzed cell surface expression of TLR2 and 4 in PU.1-overproducing cells (Fig. 3C) . Although bone marrow-derived DC expressed an apparent amount of TLR2 and 4, PU.1-overproducing cells expressed TLR2 and 4 only slightly, which was similar to the case in BMMC.
These results suggest that PU.1 enhances IL-6 production by activating downstream process of TLR-LPS/PGN interaction in TLR signaling, but not by increasing the expression of TLRs.
Response to Ag/IgE stimulation
Mast cells also produce IL-6 in response to Ag/IgE stimulation through Fc⑀RI. Although a certain kind of monocyte expresses Fc⑀RI, the response of monocytes through Fc⑀RI is markedly reduced in comparison with that of mast cells (30) . To examine the effect of PU.1 on response to Ag/IgE stimulation, we analyzed the level of IL-6 production of the cells stimulated by Ag/IgE (Fig.  4A) . The amount of IL-6 produced from PU.1-overproducing cells was markedly reduced when compared with the case of mock transfectants and control BMMC. This result indicated that overproduction of PU.1 reduced IL-6 production by interfering the signal from Fc⑀RI.
Degranulation by cross-linking of Fc⑀RI is one of the major characteristics of mast cells. Therefore, degranulation of the cells overproducing PU.1 was analyzed (Fig. 4B) . Control BMMC and mock transfectants were degranulated by stimulation with Ag/IgE to the same degree. In contrast, degranulation of the cells overproducing PU.1 was markedly decreased as well as BMDC.
From these results, it was concluded that overproduction of PU.1 reduced response to the stimulation through Fc⑀RI in mast cells.
T cell stimulation activity
Overproduction of PU.1 induced marked expression of MHC class II, which is a hallmark of APCs, on mast cells, as shown in Fig.  1C . To examine whether induced MHC class II possesses function, allostimulatory activity of transfectants cocultured with allogenic C57BL/6 CD4 ϩ T cells was measured. Thymidine incorporation of T cells was significantly increased when PU.1-overproducing cells were cocultured (Fig. 5) .
Effect of overproduction of PU.1 on PMC
PMC is connective tissue-type mast cell, which is more maturated than mucosal-type mast cell, BMMC. To examine the effect of PU.1 on connective tissue-type mast cells, PU.1 was overexpressed in freshly isolated PMC by the retrovirus vectors. The expression level of PU.1 in transfectants was increased, as was the case in BMMC (data not shown). May-Grünwald-Giemsa staining indicated that overproduction of PU.1 caused morphological change of the cells: decrease in granules accompanied by formation of vacuoles, larger veils, and lamellipodia (Fig. 6A) . Expression profile of the cell surface markers on PU.1-overproducing PMC (Fig. 6B) was somewhat different from the case of BMMC. Similar to the case in BMMC, CD11b and F4/80 were expressed and c-kit expression was suppressed on PU.1-overproducing PMC. However, expression of CD11c and MHC class II was not induced in the transfectant. Thus, increased expression of PU.1 induced several monocyte-like changes even in PMC, but the effect of PU.1 was negligible on some target molecules such as CD11b and MHC class II in PMC.
Transfection of sorted mast cells using internal ribosome entry site-GFP system to eliminate the contamination of monocyte lineages
Ten-to 20-day culture was required to select transfectants by puromycin, when plasmids pMX-puro-series were used for retrovirus transfection, as described above. Although the purity of mast cells is high (Ͼ95% for BMMC and Ͼ98% for PMC, as described in Materials and Methods), the possibility that monocytes and/or monocyte progenitors contaminated mast cell suspensions could not be excluded completely. This issue raised a possibility that contaminating monocytes and/or monocyte progenitors that were transfected with retrovirus directing to produce PU.1 proliferated more vigorously than transfected mast cells in the culture period. Therefore, to eliminate this possibility, we used purified BMMC that was collected as c-kit ϩ /Fc⑀RI ϩ cells by sorting for transfection. After 14-day culture for selection of transfectants, Ͼ98% of mock transfectants were c-kit ϩ /Fc⑀RI ϩ , while c-kit ϩ /Fc⑀RI ϩ population of ϳ94% was obtained from PU.1 transfectant (Fig. 7A) . PU.1-overproducing cells expressed CD11c, CD11b, and MHC class II, which were not expressed on mock transfectants. These results were consistent with the results of BMMC without sorting (Fig. 1C) . In addition, CD11c-, CD11b-, and MHC class II-positive cells also expressed mast cell markers, c-kit and Fc⑀RI. This result suggested that the cells expressing CD11c, CD11b, and MHC class II originated from mast cells.
To eliminate the possibility that a few contaminating monocytes and/or its progenitors grew as a major population through 20 days of culture, we constructed plasmids, pMX-IG and pMX-IG-PU.1. By infection with retrovirus, transfectants were detected as GFP ϩ cells within 2 days after transfection (Fig. 7B) . GFP ϩ population of BMMC infected with the retrovirus generated from pMX-IG-PU.1 showed reduced expression of c-kit, while GFP Ϫ population and GFP ϩ mock expressed c-kit at the level same as that of GFP Ϫ mock. PU.1-overproducing cells detected as GFP ϩ expressed CD11c and MHC class II, while most of the GFP ϩ population of mock transfectants did not express these molecules. These observations excluded the possibility that contaminating monocytes were the source of cells expressing monocyte-specific molecules. From these results, we concluded that overproduction of PU.1 in BMMC suppressed c-kit expression and induced the expression of CD11c and MHC class II.
Up-regulation of endogenous PU.1 in mast cells by LPS or PMA stimulation
Because PU.1 autoregulates its own promoter (31), the stimulation signal to activate PU.1 protein would further accelerate overexpression of PU.1. Actually, the signal to activate PU.1 protein by LPS (32) and PMA (33) induces the up-regulation of PU.1 in monocytes. Therefore, we hypothesized that mast cells and/or its progenitors might be converted to monocyte-like cells in vivo under a certain condition when either activation or up-regulation of PU.1 is induced. To evaluate the effect of LPS and PMA on PU.1 expression level in mast cells, endogenous PU.1 proteins were analyzed after stimulation of mast cells with LPS or PMA by Western blotting. Intensity of the band migrating at ϳ39 kDa was markedly increased from 4 h after LPS or PMA stimulation and decreased to background level by 24-h incubation (Fig. 8 ). An additional band migrating slower than the major band of ϳ43 kDa also appeared from 4 to 8 h after LPS or PMA stimulation. Considering that PU.1 is shown to be present in several forms with various apparent molecular mass (from 38.5 to 46.5 kDa) (1), it is likely that proteins that were recognized by anti-PU.1 Ab are PU.1. Therefore, these results indicate that endogenous PU.1 in mast cells is potentially up-regulated in a certain condition, such as stimulation with LPS or PMA.
Discussion
PU.1 is a transcription factor involved in the lymphoid-and myeloid-specific gene regulation and the development of these cell lineages. Expression level of PU.1 determines cell fate between B cells/macrophages (8) and neutrophils/macrophages (9) . In addition, overexpression of PU.1 in CD34 ϩ human myeloid progenitors promotes LC development (10, 11) . In recent analysis, we found that monocyte-specific gene expression and monocyte-like morphological change were induced by overproduction of PU.1 in mouse bone marrow-derived mast cell progenitors (12, 20, 21) . In this study, overproduction of PU.1 caused several monocyte-like characteristics on both BMMC and PMC, suggesting that developed mast cells still have the capacity to exhibit monocyte-like features.
Although the overproduction of PU.1 decreased the function and morphology of mast cells, PU.1 overproduction did not decrease the expression of Fc⑀RI, a typical marker for mast cells. In most cases, PU.1 inhibits GATA-1 to function and vice versa, possibly by forming an inactive PU.1/GATA-1 complex (34), and therefore, only either PU.1 or GATA-1 is expressed in a cell. For example, in monocyte/granulocyte lineage development from hemapoietic stem cells, stimulation signals such as GM-CSF up-regulates PU.1 expression, which subsequently inhibits the function of GATA-1 in these cells (34 -36) . However, mast cells produce both PU.1 and GATA-1, and both transcription factors trans activate the promoter of Fc⑀RI ␣-chain (37) . GATA-1 also positively regulates the transcription of another Fc⑀RI-specific component, Fc⑀RI ␤-chain (38) . In our present study, we observed that BMMC transfectants overproducing PU.1 still expressed GATA-1 at similar level as that of mock transfectants (data not shown). Therefore, we assume that GATA-1 present in the cell might assure Fc⑀RI expression even in BMMC overproducing PU.1. The mechanism allowing the copresence of both GATA-1 and PU.1 in mast cells is unclear at present. Considering that cooperative function between GATA-1 and PU.1 is involved in mast cell-specific gene regulation (7, 37, 39) , we speculate that this synergistic effect may be essential for mast cell development. In any case, further detailed analysis will be required to clarify these points.
Overproduction of PU.1 induced apparent expression of CD11b and F4/80, and suppressed c-kit expression in PMC. However, the PU.1 overproduction did not induce expression of CD11c and MHC class II in PMC, which was in contrast to the case of BMMC overproducing PU.1. These results indicated that PMC possessed lower capacity to express monocyte-specific gene than that of BMMC. We assume that this discrepancy may reflect the difference in the expression profile of other transcription factors between these cells. A transcription factor, C/EBP␣, might be one of the candidates, because C/EBP␣ is reported to inhibit development of myeloid progenitor cells to DC, which is induced by PU.1, and direct them to macrophage and granulocyte lineages (11) .
Overexpression of PU.1 in BMMC induced hyperproduction of IL-6 in response to stimulation signal through TLR2 and 4. It is suggested that PU.1 is involved in the transcriptional regulation of TLR2 and 4 (28, 29) . However, expression level of TLR2 and 4 in BMMC was not affected by overproduction of PU.1 (Fig. 3) . In addition, production of IL-6 in response to Ag/IgE stimulation was reduced (Fig. 4A) . These results suggest that PU.1 regulates IL-6 expression in a complex manner. Considering that PU.1 is activated by stimulation with LPS (32), PU.1 might function in the downstream process in TLR signaling.
PU.1 autoregulates its own promoter (31) . Therefore, the stimulation signal to activate PU.1 protein would further accelerate up-regulation of PU.1. Therefore, we hypothesize that mast cells and/or its progenitors might be converted to monocyte-like cells in vivo under a certain condition when either activation or overproduction of PU.1 is induced. We have shown that LPS and PMA stimulation induced PU.1 production in mast cells, which suggests that mast cells might be potential sources for macrophages and/or DC under certain conditions in vivo. This is the first observation in mast cells showing up-regulation of PU.1 by stimulation of LPS and PMA. However, the production of PU.1 induced by LPS or PMA stimulation was transient and markedly lower in level than that of PU.1 produced by retrovirus system. We assume that this is the reason for failure of the stimulations in converting mast cells to monocytes. To prove this possibility, further analysis will be required to optimize conditions of PU.1 induction in mast cells, which are suitable for obtaining monocyte-specific gene expression.
Recently, the presence in vivo of Fc⑀RI-positive monocytes, DC, and LC, all of which possess the Ag presentation ability, was shown (40, 41) . Considering that the marked up-regulation of Fc⑀RI expression is observed specifically on LC and DC in lesional skin of atopic dermatitis (40, 41) , we assume that above-mentioned signal to activate PU.1 might be a possible cause of the appearance of Fc⑀RI-positive monocytes, which are developed from mast cells or its progenitors in vivo. Therefore, characterization of the mechanisms for the regulation of Fc⑀RI expression on monocyte might give important information for prevention of atopic dermatitis.
GM-CSF (16) and M-CSF (42) induce development of hemopoietic progenitor cells toward DC and macrophage. In the process of monocyte development, the signal through these factors is transduced to Fes and subsequently to PU.1 (43) to induce the expression of the receptors for GM-CSF (44) and M-CSF (45). Actually, retrovirus-mediated expression of PU.1 in macrophage prepared from GM-CSF-null mice rescued the defect in differentiation (46) . Thus, it is likely that PU.1-mediated gene expression is a key event in monocyte development. However, the mechanism for both activation of PU.1 and up-regulation of PU.1 expression is mostly unknown. Therefore, further detailed analyses on upstream and downstream signaling of PU.1 are required for revealing the mechanism for monocyte lineage development.
Fukuyama and T. Tokura for technical support, and M. Matsumoto and E. Kawasaki for secretarial assistance. We are grateful to Dr. W. Ng for proofing this manuscript.
